Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Clinical trial NCT07315113 · RECRUITING

Trial details

NCT number: NCT07315113
Sponsor: Nuvectis Pharma, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

EGFR Mutation Positive Non-small Cell Lung Cancer EGFR Mutated Non-small Cell Lung Cancer Patients

Start date: 2025-12-18
Primary completion: 2026-12-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.